Study on Behavior Value Analysis and Decision Methodology of Grid Corporations in China

Based on grid corporations, business environment and value characteristics in China, the article analyzes its behavior value factors, and then divides its behavior into three categories: the behavior only affecting the current Economic Value Added(EVA), the behavior affecting both the current and future EVA, and the behavior only affecting future EVA. Finally, the article studies such corporations, behavior value decision making based upon analyses and classifications above

Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy in ES-SCLC

Immune checkpoint blockade targeting the PD-1/PD-L1 pathway in combination with platinum-based chemotherapy (CT) has demonstrated improved clinical outcomes in patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab ± Tremelimumab in combination with etoposide and platinum-based CT (EP) as first-line treatment for pts with ES-SCLC. Results will be presented at WCLC 2019 including OS, key secondary endpoints, safety and tolerability

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

Objectives In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination with either cisplatin or carboplatin (EP) significantly improved overall survival (primary endpoint) versus EP alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) at the interim analysis. Here we report patient-reported outcomes (PROs). Materials and methods Treatment-naïve patients with ES-SCLC received 4 cycles of durvalumab plus EP every 3 weeks followed by maintenance durvalumab every 4 weeks until progression, or up to 6 cycles of EP every 3 weeks. PROs, assessed with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) version 3 and its lung cancer module, the Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13), were prespecified secondary endpoints. Changes from baseline to disease progression or 12 months in prespecified key disease-related symptoms (cough, dyspnea, chest pain, fatigue, appetite loss) were analyzed with a mixed model for repeated measures. Time to deterioration (TTD) of symptoms, functioning, and global health status/quality of life (QoL) from randomization was analyzed. Results In the durvalumab plus EP and EP arms, 261 and 260 patients were PRO-evaluable. Patients in both arms experienced numerically reduced symptom burden over 12 months or until progression for key symptoms. For the improvements from baseline in appetite loss, the between-arm difference was statistically significant, favoring durvalumab plus EP (difference, −4.5; 99% CI: −9.04, −0.04; nominal p = 0.009). Patients experienced longer TTD with durvalumab plus EP versus EP for all symptoms (hazard ratio [95% CI] for key symptoms: cough 0.78 [0.600‒1.026]; dyspnea 0.79 [0.625‒1.006]; chest pain 0.76 [0.575‒0.996]; fatigue 0.82 [0.653‒1.027]; appetite loss 0.70 [0.542‒0.899]), functioning, and global health status/QoL. Conclusion Addition of durvalumab to first-line EP maintained QoL and delayed worsening of patient-reported symptoms, functioning, and global health status/QoL compared with EP

Analyzing The Value Drivers and Path Selection of Grid Corporations From the View of The Long-term Value

Based on the business characteristics and EVA, the paper develops an econometric model for the long-term value of grid corporations in China, and analyzes the value drivers and path selection correspondingly. The study shows that, the growing long-term value of grid corporations derives from the creation of future value, and the fundamental factor is an increase in investment. Grid corporations should target at investment management and capital optimization, realizing the goal of long-term value

Study on Behavior Value Analysis and Decision Methodology of Grid Corporations in China

Based on grid corporations, business environment and value characteristics in China, the article analyzes its behavior value factors, and then divides its behavior into three categories: the behavior only affecting the current Economic Value Added(EVA), the behavior affecting both the current and future EVA, and the behavior only affecting future EVA. Finally, the article studies such corporations, behavior value decision making based upon analyses and classifications above

Analyzing The Value Drivers and Path Selection of Grid Corporations From the View of The Long-term Value

Based on the business characteristics and EVA, the paper develops an econometric model for the long-term value of grid corporations in China, and analyzes the value drivers and path selection correspondingly. The study shows that, the growing long-term value of grid corporations derives from the creation of future value, and the fundamental factor is an increase in investment. Grid corporations should target at investment management and capital optimization, realizing the goal of long-term value

Study on Behavior Value Analysis and Decision Methodology of Grid Corporations in China

Based on grid corporations, business environment and value characteristics in China, the article analyzes its behavior value factors, and then divides its behavior into three categories: the behavior only affecting the current Economic Value Added(EVA), the behavior affecting both the current and future EVA, and the behavior only affecting future EVA. Finally, the article studies such corporations, behavior value decision making based upon analyses and classifications above